Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
8(80%)
Results Posted
100%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
5
50%
Ph phase_4
1
10%
Ph phase_2
4
40%

Phase Distribution

5

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

8

trials recruiting

Total Trials

10

all time

Status Distribution
Active(8)
Completed(1)
Terminated(1)

Detailed Status

Recruiting7
Terminated1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
8
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (50.0%)
Phase 24 (40.0%)
Phase 41 (10.0%)

Trials by Status

terminated110%
recruiting770%
active_not_recruiting110%
completed110%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT03670966Phase 1

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Recruiting
NCT04797767Phase 1

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Recruiting
NCT07020533Phase 1

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Recruiting
NCT07101445Phase 4

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Recruiting
NCT07046078Phase 2

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Recruiting
NCT04370301Phase 2

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting
NCT04871607Phase 2

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recruiting
NCT04195945Phase 2

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Active Not Recruiting
NCT04196010Phase 1

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

Terminated
NCT03531918Phase 1

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10